Improving the Delivery of Chronic Opioid Therapy Among People Living With Human Immunodeficiency Virus: A Cluster Randomized Clinical Trial. (22nd July 2020)

• Record Type: Journal Article
• Authors: Samet, Jeffrey H; Tsui, Judith I; Cheng, Debbie M; Liebschutz, Jane M; Lira, Marlene C; Walley, Alexander Y; Colasanti, Jonathan A; Forman, Leah S; Root, Christin; Shanahan, Christopher W; Sullivan, Margaret M; Bridden, Carly L; Abrams, Catherine; Harris, Catherine; Outlaw, Kishna; Armstrong, Wendy S; del Rio, Carlos
• Is Part Of: Clinical infectious diseases. Volume 73:Number 7(2021)
• Page Start: e2052
• Page End: e2058
• Publication Date: 2020-07-22
• Subjects: HIV -- chronic pain -- chronic opioid therapy -- prescription opioid misuse -- pain management; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa1025
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Chronic pain is prevalent among people living with human immunodeficiency virus (PLWH); managing pain with chronic opioid therapy (COT) is common. Human immunodeficiency virus (HIV) providers often diverge from prescribing guidelines. Methods: This 2-arm, unblinded, cluster-randomized clinical trial assessed whether the Targeting Effective Analgesia in Clinics for HIV (TEACH) intervention improves guideline-concordant care compared to usual care for PLWH on COT. The trial was implemented from 2015 to 2018 with 12-month follow-up at safety-net hospital–based HIV clinics in Boston and Atlanta. We enrolled 41 providers and their 187 patients on COT. Prescribers were randomized 1:1 to either a 12-month intervention consisting of a nurse care manager with an interactive electronic registry, opioid education, academic detailing, and access to addiction specialists or a control condition consisting of usual care. Two primary outcomes were assessed through electronic medical records: ≥2 urine drug tests and any early COT refills by 12 months. Other outcomes included possible adverse consequences. Results: At 12 months, the TEACH intervention arm had higher odds of ≥2 urine drug tests than the usual care arm (71% vs 20%; adjusted odds ratio [AOR], 13.38 [95% confidence interval {CI}, 5.85–30.60]; P < .0001). We did not detect a statistically significant difference in early refills (22% vs 30%; AOR, 0.55 [95% CI, .26–1.15]; P = .11), pain severity (6.30 vs 5.76; adjusted mean difference, 0.10 [95% CI, −1.56 to 1.75]; P = .91), or HIV viral load suppression (86.9% vs 82.1%; AOR, 1.21 [95% CI, .47–3.09]; P = .69). Conclusions: TEACH is a promising intervention to improve adherence to COT guidelines without evident adverse consequences. Abstract : In this cluster randomized clinical trial of human immunodeficiency virus (HIV) providers and patients, the TEACH intervention resulted in improved adherence to opioid prescribing guidelines. TEACH is a promising intervention to improve adherence to chronic opioid therapy guidelines for people with HIV.